Return to search

The interface of COVID-19, diabetes, and depression

Comorbid diabetes with depression is a challenging and often under-recognized clinical problem. During the current COVID-19 pandemic, a communicable disease is thriving on the increasing incidences of these non-communicable diseases. These three different health problems are bidirectionally connected forming a vicious cycle. Firstly, depressed individuals show a higher risk of developing diabetes and patients with diabetes have a higher risk of developing symptoms of depression. Secondly, patients with diabetes have a higher risk of developing severe COVID-19 as well as of experiencing breakthrough infections. Thirdly, in both patients with type 2 diabetes and in COVID-19 survivors the prevalence of depression seems to be increased. Fourthly, lockdown and quarantine measurements during the COVID-19 pandemic has led to an increase in depression. Therefore, it is of importance to increase the awareness of this interface between depression, diabetes and COVID-19. Finally, as symptoms of post-COVID, diabetes and depression may be overlapping, there is a need for educating skilled personnel in the management of these comorbidities.

Identiferoai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:90450
Date08 April 2024
CreatorsSteenblock, Charlotte, Schwarz, Peter E. H., Perakakis, Nikolaos, Brajshori, Naime, Beqiri, Petrit, Bornstein, Stefan R.
PublisherSpringer International Publishing
Source SetsHochschulschriftenserver (HSSS) der SLUB Dresden
LanguageEnglish
Detected LanguageEnglish
Typeinfo:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text
Rightsinfo:eu-repo/semantics/openAccess
Relation2731-4383, 5, 10.1007/s44192-022-00007-0, info:eu-repo/grantAgreement/Deutsche Forschungsgemeinschaft/Transregios/314061271//TRR 205: Die Nebenniere: Zentrales Relais in Gesundheit und Krankheit, info:eu-repo/grantAgreement/Deutsche Forschungsgemeinschaft/Internationale Graduiertenkollegs/288034826//GRK 2251: Immunologische und zellbasierte Strategien bei metabolischen Erkrankungen

Page generated in 0.0017 seconds